PMID- 32827084
OWN - NLM
STAT- MEDLINE
DCOM- 20211007
LR  - 20211007
IS  - 1573-2576 (Electronic)
IS  - 0360-3997 (Linking)
VI  - 44
IP  - 1
DP  - 2021 Feb
TI  - T2 Peptide Represents a Major Autoantigen Epitope in Experimental Autoimmune 
      Prostatitis.
PG  - 243-248
LID - 10.1007/s10753-020-01326-6 [doi]
AB  - Chronic prostatitis/chronic pelvic pain syndromes (CP/CPPS) is a clinical tricky 
      problem due to its enigmatic etiology, low cure rate, and high recurrence rate. 
      The research on its pathogenesis has never stopped. In this experimental 
      autoimmune prostatitis (EAP) model, male C57BL/6 mice were subcutaneously 
      immunized with prostate extracts in an adequate adjuvant. For mice in the 
      antibody intervention group, anti-T2 polyclonal antibodies were intraperitoneally 
      injected during the induction of EAP. Animals were periodically monitored for 
      pelvic pain. Hematoxylin and eosin staining was used to assess prostate 
      inflammation. Tumor necrosis factor-alpha (TNF-alpha) levels in serum were measured by 
      ELISA kits. The immunized animals developed prostatitis as a consequence of the 
      immune response against prostate antigens. Pelvic pain thresholds were gradually 
      decreased and TNF-alpha expression significantly increased. T2 plays an important 
      role in the disease since polyclonal antibodies to T2 greatly ameliorated 
      symptoms in animals induced for EAP. T2 peptide may represent the major 
      autoantigen epitope in EAP, which could serve for a better understanding of the 
      etiology of CP/CPPS.
FAU - Liu, Yuqian
AU  - Liu Y
AD  - Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, China.
FAU - Tang, Meng
AU  - Tang M
AD  - Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, China.
FAU - Zhang, Qin
AU  - Zhang Q
AD  - Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, China.
FAU - Li, Cuican
AU  - Li C
AD  - Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, China.
FAU - Lv, Rundong
AU  - Lv R
AD  - Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, China.
FAU - Min, Hanhui
AU  - Min H
AD  - Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, China.
FAU - Zhou, Xiaohui
AU  - Zhou X
AUID- ORCID: 0000-0003-2610-4388
AD  - Department of Clinical Pharmacy, School of Basic Medicine and Clinical Pharmacy, 
      China Pharmaceutical University, Nanjing, 211198, Jiangsu Province, China. 
      zhxh@cpu.edu.cn.
AD  - Department of Surgery, Nanjing Shuiximen Hospital, Nanjing, Jiangsu Province, 
      210017, People's Republic of China. zhxh@cpu.edu.cn.
AD  - Zhongda Hospital, Affiliated with Southeast University, Nanjing, 210017, Jiangsu 
      Province, China. zhxh@cpu.edu.cn.
LA  - eng
PT  - Journal Article
DEP - 20200822
PL  - United States
TA  - Inflammation
JT  - Inflammation
JID - 7600105
RN  - 0 (Autoantigens)
RN  - 0 (Epitopes)
RN  - 0 (Peptide Fragments)
SB  - IM
MH  - Amino Acid Sequence
MH  - Animals
MH  - Autoantigens/*blood/immunology
MH  - Autoimmune Diseases/*blood/immunology/prevention & control
MH  - Epitopes/*blood/immunology
MH  - Male
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Pelvic Pain/*blood/immunology/prevention & control
MH  - Peptide Fragments/*antagonists & inhibitors/blood/immunology
MH  - Prostatitis/*blood/immunology/prevention & control
MH  - Rabbits
OTO - NOTNLM
OT  - Autoantigen epitope
OT  - Autoimmune disease
OT  - Chronic prostatitis/chronic pelvic pain syndrome
OT  - T2 peptide
EDAT- 2020/08/23 06:00
MHDA- 2021/10/08 06:00
CRDT- 2020/08/23 06:00
PHST- 2020/03/24 00:00 [received]
PHST- 2020/08/18 00:00 [accepted]
PHST- 2020/08/02 00:00 [revised]
PHST- 2020/08/23 06:00 [pubmed]
PHST- 2021/10/08 06:00 [medline]
PHST- 2020/08/23 06:00 [entrez]
AID - 10.1007/s10753-020-01326-6 [pii]
AID - 10.1007/s10753-020-01326-6 [doi]
PST - ppublish
SO  - Inflammation. 2021 Feb;44(1):243-248. doi: 10.1007/s10753-020-01326-6. Epub 2020 
      Aug 22.